Yago Garitaonaindia
Overview
Explore the profile of Yago Garitaonaindia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garitaonaindia Y, Martinez-Cutillas M, Uribarren M, Redondo I, Calvo V, Serna-Blasco R, et al.
Clin Transl Oncol
. 2025 Jan;
PMID: 39789380
This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment...
2.
She W, Garitaonaindia Y, Lin Y
Transl Lung Cancer Res
. 2024 Dec;
13(11):3241-3251.
PMID: 39669995
Background And Objective: Liquid biopsy has emerged as a transformative approach in the diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated overview of the...
3.
Sanchez J, Nunez-Garcia B, Garitaonaindia Y, Calvo V, Blanco M, Ramos Martin-Vegue A, et al.
Clin Transl Oncol
. 2024 Aug;
PMID: 39147937
Purpose: The complexity of cancer care requires planning and analysis to achieve the highest level of quality. We aim to measure the quality of care provided to patients with non-small...
4.
Garitaonaindia Y, Mendez M, Valentin F, Gutierrez L, Herreros de Tejada A, Sanchez Ruiz A, et al.
Mol Genet Genomic Med
. 2024 Jul;
12(7):e2496.
PMID: 39056403
Background: Hereditary diffuse gastric cancer (HDGC) (OMIM# 137215) is an autosomal dominant cancer syndrome associated with CDH1 (OMIM# 192090) mutations. Prophylactic total gastrectomy (PTG) is the most recommended preventive treatment...
5.
Garitaonaindia Y, Aguado-Noya R, Garcia-Grande A, Cordoba M, Coronado Albi M, Campo Canaveral J, et al.
Transl Lung Cancer Res
. 2023 Aug;
12(7):1414-1424.
PMID: 37577300
Background: Surgery is regarded as the treatment's cornerstone for early stage and locally advanced non-small cell lung cancer (NSCLC) whenever the tumor is considered resectable. Liquid biopsy is one of...
6.
Nunez-Garcia B, Clemente M, Sanchez J, Royuela A, Cantos Sanchez de Ibarguen B, Mendez M, et al.
Hematol Oncol
. 2023 Mar;
41(3):407-414.
PMID: 36934306
The high cure rates of Hodgkin lymphoma (HL) make this oncological disease among those with the greatest number of long-term survivors. This single-institution study including 383 HL patients with up...
7.
Rodriguez-Cano F, Calvo V, Garitaonaindia Y, Campo-Canaveral de la Cruz J, Blanco M, Torrente M, et al.
Transl Lung Cancer Res
. 2023 Mar;
12(2):247-256.
PMID: 36895936
Background: Many patients with non-metastatic non-small cell lung cancer (NSCLC) are cured by surgery but part of them develop recurrence. Strategies are needed to identify these relapses. Currently, there is...
8.
Torrente M, Blanco M, Franco F, Garitaonaindia Y, Calvo V, Collazo-Lorduy A, et al.
Front Cardiovasc Med
. 2022 Dec;
9:1062858.
PMID: 36531707
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon...
9.
Paez-Guillan E, Campos-Franco J, Alende R, Garitaonaindia Y, Gonzalez-Quintela A
Lipids Health Dis
. 2021 Dec;
20(1):177.
PMID: 34895245
Background: Hypertriglyceridemia can occur in lymphoproliferative disorders. Infectious mononucleosis is a self-limiting, benign lymphoproliferative disorder. This study aimed to investigate the serum triglyceride concentrations and their change over time in...
10.
Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34446577
Background: Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains...